H.C. Wainwright lowered the firm’s price target on Xoma (XOMA) to $104 from $123 and keeps a Buy rating on the shares. The firm removed iscalimab from its projections.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Questions or Comments about the article? Write to editor@tipranks.com